“Revolutionizing Weight Loss: Novo Nordisk’s Subcutaneous Amycretin Trial Shows Promising Results”
Novo Nordisk Announces Breakthrough in Obesity Treatment Early-Stage Trial Results Show Promise for Amycretin Drug Novo Nordisk made headlines on Friday with the announcement of early-stage trial results for its amycretin obesity drug. The pharmaceutical company reported that individuals with obesity or overweight who were treated with the drug experienced an impressive 22% weight loss…